Tirzepatide Dosage: What the Phase 3 Programme Documented

The short version

Tirzepatide is an FDA-approved medicine given as a once-weekly subcutaneous (under the skin) injection. In every phase 3 trial, dosing started at 2.5 mg per week and stepped up gradually — 2.5 mg every four weeks — to allow the body time to adjust before reaching the maintenance dose. The final maintenance doses studied in phase 3 were 5, 10, and 15 mg once weekly. The dose-response was clear: higher doses produced larger reductions in blood sugar and body weight, but also somewhat higher rates of gastrointestinal side effects like nausea.

The half-life of approximately five days means the drug reaches steady-state levels over four to five weeks. Once-weekly dosing keeps blood levels stable without the peaks and troughs you would get with a daily injection. This pharmacokinetic profile — conferred by the fatty-diacid modification that lets the drug bind albumin in the bloodstream — is designed into the molecule's structure ^[1].

This page summarises what the clinical programme documented. For information on the approved prescribing schedule for an indicated condition, the FDA prescribing information is the authoritative source.

Tirzepatide dosage: the clinical trial titration schedule

In the SURPASS and SURMOUNT phase 3 programmes, tirzepatide dosage followed a fixed stepwise titration schedule. The schedule used across the major trials was ^[1][3][4]:

• Weeks 1–4: 2.5 mg once weekly
• Weeks 5–8: 5.0 mg once weekly
• Weeks 9–12: 7.5 mg once weekly
• Weeks 13–16: 10.0 mg once weekly
• Weeks 17–20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (maximum dose arm)

Participants in the lower-dose arms of the SURPASS programme were maintained at 5 mg, 10 mg, or 15 mg once weekly from their respective target doses. The SURMOUNT programme similarly used 5, 10, and 15 mg once weekly as the three maintenance doses after the 20-week escalation period ^[4].

The rationale for the stepwise titration is tolerability: gastrointestinal adverse events (nausea, vomiting, diarrhoea, constipation) are dose-dependent and most common during escalation, attenuating with continued exposure at a stable dose. The slow step-up schedule is designed to allow the GI system to adapt between each step ^[13].

The FDA-approved prescribing information for the indicated uses specifies the same stepwise schedule and maintenance dose range. The starting dose of 2.5 mg is a dose-finding dose only — not a therapeutic maintenance dose.

Tirzepatide dose and exposure-response

The dose-response relationship across both programmes was consistent:

Type 2 diabetes (SURPASS-2, 40 weeks) ^[3]:

• 5 mg: HbA1c reduction 2.01 percentage points
• 10 mg: HbA1c reduction 2.24 percentage points
• 15 mg: HbA1c reduction 2.30 percentage points
• Comparison: semaglutide 1 mg: 1.86 percentage points

Obesity without diabetes (SURMOUNT-1, 72 weeks) ^[4]:

• 5 mg: mean body weight change -15.0%
• 10 mg: mean body weight change -19.5%
• 15 mg: mean body weight change -20.9%
• Placebo: mean body weight change -3.1%

Higher doses consistently produced larger effects at the cost of numerically higher gastrointestinal event rates during escalation.

Pharmacokinetics: half-life and steady-state

Tirzepatide's elimination half-life of approximately five days is the pharmacokinetic property that enables once-weekly dosing ^[1]. The half-life is conferred by the compound's C20 fatty-diacid modification: the eicosanedioic acid moiety attached to a lysine residue via a glutamic acid linker allows reversible, non-covalent binding to plasma albumin. Albumin binding protects the peptide from renal clearance and enzymatic degradation, dramatically extending its time in circulation relative to the native GIP and GLP-1 peptides (which have half-lives of minutes).

With a five-day half-life, steady-state plasma concentrations are reached after approximately three to four weeks of once-weekly dosing. This means the full pharmacodynamic effect of any given dose level is not seen until roughly a month after the dose is reached.

The half-life also means that after discontinuation, the compound clears over approximately three to four weeks. The weight regain data from SURMOUNT-4 and the systematic review of discontinuation outcomes confirm that the metabolic benefits depend on continued exposure ^[28][29].

Tirzepatide side effects: dose dependence

Gastrointestinal tirzepatide side effects — nausea, vomiting, diarrhoea, constipation, decreased appetite — were the most common adverse effects across the phase 3 programme. They were dose-dependent and most prevalent during dose escalation, with rates generally higher at 10 mg and 15 mg than at 5 mg. In SURMOUNT-1, discontinuation due to adverse events occurred in 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) of participants versus 2.6% with placebo ^[4].

A systematic review and meta-analysis of nine RCTs (9,871 participants) confirmed the gastrointestinal adverse-event profile and documented that the composite gallbladder or biliary disease risk was significantly increased versus controls (RR 1.97, 95% CI 1.14–3.42) across the dose range ^[6].

Tirzepatide vs semaglutide: dose and efficacy comparison

The direct head-to-head comparison in type 2 diabetes (SURPASS-2) compared tirzepatide 5, 10, and 15 mg once weekly against semaglutide 1 mg once weekly — the established high-efficacy dose — over 40 weeks. Tirzepatide was superior at all three doses on the primary HbA1c endpoint and produced greater body weight reductions at all doses ^[3].

SURMOUNT-5 compared the maximum tolerated doses of tirzepatide (10 or 15 mg) against the maximum tolerated dose of the comparison drug (1.7 or 2.4 mg) in adults with obesity but without type 2 diabetes. At 72 weeks, tirzepatide produced 20.2% versus 13.7% mean body weight reduction — a statistically significant and clinically meaningful difference ^[5].

The tirzepatide vs semaglutide comparison across these two trials establishes that for both glycaemic control in T2D and weight reduction in obesity, the dual incretin mechanism produces larger effects than selective GLP-1 agonism at the dose levels studied.

For the full mechanistic explanation of why, see tirzepatide mechanism of action.